Quantcast

Latest Oncolytic virus Stories

2011-04-20 06:30:00

CALGARY, April 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC) (NASDAQ: ONCY) today announced interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases. The principal investigator of the study was Professor Alan Melcher of Leeds Institute of Molecular Medicine, University of Leeds, UK. The trial was an...

2011-04-11 17:03:17

Targeted photodynamic therapy can completely eradicate some models of cancer, according to the latest research by UK and Swiss scientists, published in the current issue of the British Journal of Cancer. The team "“ including researchers from the University of Hull and ETH Zurich "“ linked light-sensitive molecules with antibodies that target tumour blood vessels. When irradiated with light, the molecules create particles known as reactive oxygen species, which in high numbers...

2011-04-06 01:00:00

SAN FRANCISCO and ILLKIRCH, France, April 6, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, reported interim results from Phase 1 dose-escalation clinical trials demonstrating that administration of JX-594...

2011-04-05 01:00:00

SAN FRANCISCO and ILLKIRCH, France, April 5, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that new data from Phase 1 and 2 clinical studies of JX-594 were presented in an oral presentation...

2011-03-24 06:30:00

CALGARY, March 24 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC, NASDAQ: ONCY) today announced that it has completed patient enrollment in its U.S. Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. "This study was performed in part to confirm the results of our UK Phase II study, which enrolled a slightly different patient population, and to...

2011-03-14 16:14:32

The research points to a clear strategy for identifying the subset of liver cancer patients who might benefit from treatment with a therapeutic monoclonal antibody In a research study appearing in the journal Cancer Cell on March 14, scientists from Cold Spring Harbor Laboratory (CSHL) and four other institutions have identified a strategy for targeted molecular therapy in liver cancer, which currently has limited treatment options and one of the worst one-year survival rates of any cancer...

2011-02-23 06:30:00

CALGARY, Feb. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC) (NASDAQ: ONCY) announced today that enrollment has been completed in a U.K. translational clinical trial investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases (REO 013). The principal investigator is Professor Alan Melcher of St. James's University Hospital and the trial is sponsored by the University...

2011-02-22 06:00:00

SAN FRANCISCO, Feb. 22, 2011 /PRNewswire/ -- Jennerex, Inc. (San Francisco), a clinical-stage cancer biotherapeutics company, today announced the appointment of James M. Burke, M.D. to the newly-created position of vice president, clinical research. Dr. Burke will be responsible for all global clinical research activities related to Jennerex pipeline compounds. "Dr. Burke has been working with Jennerex in an advisory capacity as a clinical advisor for over a year, and has provided...

2011-02-09 03:59:00

HELSINKI, February 9, 2011 /PRNewswire/ -- Oncos Therapeutics, a biotech company developing novel cancer therapeutics based on its next generation oncolytic viruses, announced today the appointment of Dr. Mikael von Euler, MD, PhD, FFPM, as Chief Medical Officer. Earlier this year, the Company announced the appointments of Dr. Jonathan Knowles and Dr. Robert Burns to its Board of Directors. "Oncos has already treated over 200 patients across different solid tumor types with many...

2011-01-19 06:00:00

SAN FRANCISCO, Jan. 19, 2011 /PRNewswire/ -- Jennerex, Inc. (San Francisco), a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today announced the appointment of Ursula Fritsch to the newly-created position of vice president, regulatory affairs. Dr. Fritsch will be responsible for developing global regulatory strategies and managing all aspects of regulatory affairs for all Jennerex pipeline product candidates....


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.